ArticleAmerican journal of cancer research2026
Comparative efficacy and safety of bispecific antibody teclistamab versus CAR-T cell therapies in relapsed/refractory multiple myeloma: a retrospective evaluation.
Yanjun Guo et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.